Temasek will invest $800 million in Verily for a minority stake in the company. Additionally, Temasek will nominate a director to Verily’s operating board.
Temasek has a net portfolio value of $180 billion, predominantly in Singapore and Asia. However, the investment company recently announced an increased focus on North American technology ventures. It established an office in San Francisco in late 2016.
Verily, a life sciences research and engineering organization, focuses on improving healthcare outcomes by combining data organization and analytics services with scientific and product engineering expertise. It partners with life sciences, medical device and government organizations.
Verily will receive a majority of Temasek’s investment in the near future and the remainder in the second half of 2017.
More articles on health IT:
Viewpoint: Longer lifespans aren’t to blame for rising healthcare costs
Lundbeck, IBM Watson Health partner to develop psychiatric drugs
ONC: Immunization, laboratory results top list of most reported public health data
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.